June 9, 2016
Shionogi will transfer three off-patent brand-name cancer drugs (six products) to Japanese generic major Nichi-Iko Pharmaceutical in a bid to sharpen its focus on innovative medicines. Nichi-Iko said on June 8 that the marketing authorization for the three drugs -...read more